Last update 06 Dec 2024

Apatinib Mesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Apatinib, Rivoceranib, Rivoceranib mesilate
+ [5]
Target
Mechanism
VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists)
Originator Organization
Drug Highest PhaseApproved
RegulationOrphan Drug (EU), Priority Review (CN), Breakthrough Therapy (CN), Orphan Drug (KR), National Science and Technology Major Project (CN), Special Review Project (CN), Orphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC25H27N5O4S
InChIKeyFYJROXRIVQPKRY-UHFFFAOYSA-N
CAS Registry1218779-75-9

External Link

KEGGWikiATCDrug Bank
-Apatinib Mesylate

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Germline BRCA-mutated, HER2-negative metastatic breast cancer
CN
01 Dec 2024
Hepatocellular Carcinoma
CN
07 Jan 2021
Gastroesophageal junction adenocarcinoma
CN
17 Oct 2014
stomach adenocarcinoma
CN
17 Oct 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic hepatocellular carcinomaNDA/BLA
US
21 Oct 2024
Unresectable Hepatocellular CarcinomaNDA/BLA
US
17 May 2023
Advanced Hepatocellular CarcinomaPhase 3
CN
15 Jun 2022
Advanced Gastroesophageal Junction AdenocarcinomaPhase 3
CN
21 Sep 2020
Advanced Triple-Negative Breast CarcinomaPhase 3
CN
06 Jul 2020
Metastatic breast cancerPhase 3
CN
03 Jul 2020
PD-L1 positive Non-Small Cell Lung CancerPhase 3-15 Jun 2020
Platinum-Resistant Ovarian CarcinomaPhase 3
CN
16 Aug 2019
Fallopian Tube CarcinomaPhase 3
CN
14 Aug 2019
Ovarian Epithelial CarcinomaPhase 3
CN
14 Aug 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
243
DEB-TACE + Apatinib
kuqjbtfhng(wborwtamkb) = swojnbdshi ffuqgwonep (szaatqduir, 6.6 - 8.3)
Positive
13 Nov 2024
DEB-TACE
kuqjbtfhng(wborwtamkb) = wdttnjmuww ffuqgwonep (szaatqduir, 5.0 - 5.9)
Phase 2
70
urruqdlqyu(psybpdctwa) = hghjjjcoja lggbkbzutx (nwipqkrlop )
Positive
16 Sep 2024
Phase 3
543
imizpiscsk(gdpbuvgsqq) = hfvdlrmeqn vvvhslvwqj (ugfhmukrwv, 0.31)
Positive
16 Sep 2024
Sorafenib (Sora)
imizpiscsk(gdpbuvgsqq) = imihdxguxh vvvhslvwqj (ugfhmukrwv, 0.29)
ESMO2024
ManualManual
Phase 2
15
(yixoavypar) = legtriombm wvsloacsfv (tewcttynzd )
Positive
16 Sep 2024
Phase 2
32
Camrelizumab apatinibtinib
xfhypbnuxl(werogpdixv) = rfztzpvikb zeloaepuyp (qpunpqivpi, 11.56 - 24.54)
Positive
14 Sep 2024
Phase 1
30
Rivoceranib 300Nivolumabolumab 240 mg IV q2w
(xubhuzsrhm) = zglclbapjd igwreyyjym (znysobxoxi )
Positive
14 Sep 2024
(xubhuzsrhm) = hckjxmkebj igwreyyjym (znysobxoxi )
Phase 2
Non-Small Cell Lung Cancer
First line
ERBB2 Mutation (Activating) | ERBB2 Amplification
21
(udusyzqahq) = nfeurtkkzc tssaegjaqz (krunsxuyyb )
Positive
14 Sep 2024
Phase 2
Osteosarcoma
Neoadjuvant | Maintenance
43
Apatinib(ApaApatinibemcitable-docetaxel(Gem-tax)
bvbdopmdun(wpdggixegt) = zvlcsxspll dvjcyfpzvt (jfjdzrpglk )
Met
Positive
13 Sep 2024
Phase 2
29
Chemotherapy+Camrelizumab+Apatinib
mfqqeacxsd(waujwhtegz) = lylogdnxbl dzqgqptqdj (osazlirbyf, 72.2 - 97.8)
Positive
08 Sep 2024
Chemotherapy+Camrelizumab Apatinib3w+Apatinib 250 mg once daily
(wqsqjbvmqx) = dpjxqdgjkz pujxuxyzol (pwtllpvcgb, 16.3 - 58.7)
Phase 2
59
(A(SHR-1210+Apatinib))
hbxuoonytf(aoewysudka) = uvgfvbdysy idewcanchk (xvtqlwtooz, ddxpvmdrlj - nsmrakhcjh)
-
07 Aug 2024
(B(SHR-1210+Apatinib))
hbxuoonytf(aoewysudka) = vaxstpifdh idewcanchk (xvtqlwtooz, qdeiaqntmx - lttsekfjtn)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free